• NIAID issues a press release with preliminary results from the Adaptive COVID-19 Treatment Trial (ACCTT) of twice-daily infusions of remdesivir in hospitalized patients. It reported that remdesivir shortened the time to hospital release by 31% from a median of 15 days to 11 days. There was a numerical – but not statistically significant – difference in survival, with a death rate of 8% among people treated with remdesivir vs. 11.6% among people who got placebo. Source
• US President Trump asks the FDA to move as quickly as they can to approve remdesivir, saying ““We would like to see very quick approvals, especially with things that work.” Source
